CA017-078 Trial: Does Perioperative Nivolumab Add Benefit in MIBC?
oncodaily - The phase III CA017-078 (ENERGIZE) trial did not meet its co-primary endpoints of event-free survival (EFS) and pathological complete response (pCR). Adding nivolumab to neoadjuvant gemcitabine–cisplatin, followed by radical cystectomy […]
AI Summary: CA017‑078 examined perioperative nivolumab in muscle‑invasive bladder cancer and produced outcomes that have clinicians asking whether routine perioperative immunotherapy is justified. Critics point to mixed benefit magnitude and patient selection concerns; proponents cite potential disease control. The debate now centers on which patients truly gain meaningful survival advantage.
Related Stories
Trastuzumab rezetecan (HORIZON‑Breast06) slashes progression risk by 73% / 14 hrs
ENZAMET trial confirms long-term survival benefit of enzalutamide in mHSPC / 2 months
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 3 months
Teclistamab shows survival benefit prompting earlier use discussions / 4 months
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 6 months
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 6 months
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 6 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Healthcare Finance, Health Disparities, Eli Lilly, Pancreatic Cancer and look for the RSS link.
StackHealth Time Machine